LONDON (Alliance News) - Redx Pharma PLC on Wednesday said it has made progress on a treatment for gonorrhoea and remains confident on the rest of its drug development portfolio.
In a statement to be given to its annual general meeting, Chairman Frank Armstrong said the company has now reached the pre-clinical proof-of-concept stage for an anti-infective lead product with the potential to treat gonorrhoea, a sexually-transmitted disease.
Armstrong said the product is the second proof-of-concept Redx has delivered from its anti-infectives pipeline in the past 18 months, in line with the progress the group is making across its development portfolio.
He added the company's candidate from its Porcupine development programme, a cancer treatment, continues to offer good potential and, alongside its MRSA compound, is expected to enter first in-human clinical trials in 2017.
Redx Pharma shares were untraded at 40.89 pence Wednesday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
